Biotech
Commented by Fabian Lorenz on August 24th, 2026 | 07:35 CEST
Share Price Surges and Buy Ratings: New Price Target for Almonty as CTS EVENTIM and BioNTech Stage Comebacks
What a comeback! Almonty's share price surged by more than 50% in August! There are good reasons for the rally. Tungsten is in short supply in the West and is urgently needed due to the ramp-up in weapons production in the US. In addition, Almonty has released convincing quarterly results and announced a share buyback program. Analysts have recently nearly doubled their price target. BioNTech's share price jump of over 25% is less attributable to the biotech company itself; the stock has benefited from the breakthrough achieved by rival Moderna. Meanwhile, long-term performer CTS EVENTIM also made a comeback last week. Does this mean the stock is returning to its long-term uptrend? Analysts recommend the share as a "Buy".
Read
Commented by Matthias Schomber on August 21st, 2026 | 08:50 CEST
Short Squeeze, Takeover Battle and Military Contract – Why Novavax, Commerzbank and HPQ Silicon Could Electrify the Markets!
Three stocks, three opportunities. While Novavax could be heading for a short squeeze, aided by peer Moderna and a high short-interest ratio, a decisive turning point could be emerging in Commerzbank's multibillion-euro takeover battle with UniCredit. Away from these two companies, the greentech specialist HPQ Silicon is celebrating an operational milestone with its first military contracts for its new battery cells and is positioning itself for a technical breakout. Where do the greatest return potentials lie, and what should investors know right now? We provide the answers.
Read
Commented by Stefan Bode on August 21st, 2026 | 07:30 CEST
Three Stocks, Three Themes: Rally, Crash, and Comeback Potential—Lahontan Gold, Moderna and PFISTERER
Record profits, yet double-digit share price losses. On the stock market, it is not just earnings that count—it is the outlook for the future. That is precisely where some of the most interesting opportunities can emerge. We highlight a cyclical infrastructure stock with slowing momentum, a biotech company following a major medical breakthrough, and a commodities player benefiting from higher gold prices and project progress. Investors looking to determine whether these moves reflect market overreaction or genuine new developments will find the decisive signals in the numbers and outlooks.
Read
Commented by Carsten Mainitz on August 19th, 2026 | 07:55 CEST
Weight-Loss Boom 2.0: BioNxt Solutions, Novo Nordisk and Nestlé Are Growing in a Billion-Dollar Market
The weight-loss injection has not only transformed the pharmaceutical market but is also gradually impacting the food industry. The prescription drug semaglutide, used to treat type 2 diabetes and obesity, is at the forefront of this trend. The active ingredient mimics the body's own gut hormone GLP-1, thereby achieving several desired effects. It increases feelings of fullness, reduces appetite, slows gastric emptying, and improves insulin secretion. Meanwhile, innovative specialists such as BioNxt Solutions are positioning themselves by advancing alternative and improved drug delivery methods. The Canadian company is developing thin films of active ingredients that dissolve under the tongue and are intended to replace medications administered via injection or traditional tablets. The news flow is promising. At the same time, Nestlé is creating a new food category for people who want to lose weight using GLP-1 preparations. Who has the edge?
Read
Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST
Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca
According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.
Read
Commented by Jens Castner on August 13th, 2026 | 08:00 CEST
Berkshire Hathaway, Novo Nordisk & Zefiro Methane: Do Good and Profit From It – Up to 250% Potential!
Berkshire Hathaway and Novo Nordisk have clearly exceeded expectations with their latest quarterly results. We take a closer look at these two heavyweights—and in the process, we also turn our attention to a small environmental services provider that, according to analysts, could offer significant potential for a tenfold return. Zefiro Methane embodies one of Warren Buffett's mottos particularly closely: do good and talk about it—or, even better, do good and make money from it.
Read
Commented by Armin Schulz on August 12th, 2026 | 07:05 CEST
Three Paths to the Cancer Drug of the Future: BioNTech, Vidac Pharma, and Pfizer Under the Oncology Spotlight
Oncology has become the most dynamic field of innovation in the pharmaceutical industry. The focus is not on finding a miracle cure, but rather on developing highly precise, personalized therapies that target tumors at the molecular level. For investors, this market, which is growing at double-digit rates, is attractive in the long term. While there is a world of difference between established corporations and agile biotech companies with groundbreaking technology platforms, both offer enormous potential for value appreciation. Today, we take a look at three companies that are aiming to discover the next blockbuster drug: BioNTech, Vidac Pharma and Pfizer.
Read
Commented by Tarik Dede on August 11th, 2026 | 07:20 CEST
Pharma and Biotech Stocks in the Spotlight: Moderna, BioNxt Solutions, and Eli Lilly
Many patents held by the major pharmaceutical giants are set to expire in the coming years. Once that protection is gone, companies face the risk of lost revenue due to copycat drugs, known as generics. Consequently, the stakes are currently very high in the industry. Acquisitions and massive investments in the research pipeline are shaping the landscape. The markets for oncology and weight-loss injections are particularly lucrative. The former is a matter of life and death, while the latter is mostly about appearance and health. At the same time, many countries need to reduce their healthcare costs. Demographic trends and many lifestyle-related diseases are taking their toll on people and health insurance premiums. For investors, this tension presents a wealth of opportunities. We are therefore taking a look today at the stocks of Moderna, BioNxt Solutions, and Eli Lilly.
Read
Commented by Fabian Lorenz on August 7th, 2026 | 07:20 CEST
Comeback Opportunity or Cause for Caution? Gerresheimer, Novo Nordisk, and American Atomics
Novo Nordisk shares have plummeted by about 10% in just a few trading days. This brings the pharmaceutical giant's rally, which began in April, to an end for the time being. Disappointing clinical trial results, combined with a smaller-than-expected increase to the company's full-year guidance, left investors underwhelmed. American Atomics, on the other hand, may represent a potential turnaround story. The company is working to establish an integrated value chain in the uranium sector. Given the global expansion targets for nuclear power plants, there can be little doubt that the company can expect strong demand for uranium. There are also hopes for a recovery at Gerresheimer. The sale of several business units has generated more than EUR 1 billion in proceeds for the struggling packaging specialist. Investors are now debating whether the transaction marks a genuine strategic turning point—or whether the company is simply selling valuable assets to address near-term financial challenges.
Read
Commented by Matthias Schomber on August 6th, 2026 | 07:30 CEST
Billions Lost at BioNTech, TeamViewer Hopes for a Turnaround, and Lahontan Gold Poised for a Breakout?
Welcome to today's market update, featuring three companies at very different stages of their development. On one side is Mainz-based flagship company BioNTech, which, following the COVID-19 boom, is now grappling with a sharp decline in earnings and the painful departure of its prominent founders. Meanwhile, software developer TeamViewer is working to regain investor confidence through a comprehensive strategic transformation that is beginning to show early signs of progress. At the same time, while uncertainty continues to surround these well-known technology and healthcare companies, a much smaller resource company may be on the verge of a significant move. Lahontan Gold has reported highly encouraging drilling results and could soon be approaching a technical breakout. Let's take a closer look at these three companies to identify where the most compelling investment opportunities may lie. Read on for the full analysis.
Read